Literature DB >> 8212822

Simultaneous active and passive immunization against hepatitis A studied in a population of travellers.

G Wagner1, D Lavanchy, R Darioli, A Pécoud, V Brulein, A Safary, P C Frei.   

Abstract

Three hundred travellers, seronegative for hepatitis A, were enrolled into this study to evaluate a new inactivated hepatitis A vaccine. Three injections, each containing at least 720 ELISA units, were administered intramuscularly at months 0, 1 and 6. The subjects were distributed into three groups: 100 received vaccine only; 100 received a single injection of immunoglobulin enriched in HAV antibody; and the 100 remaining travellers received the vaccine and immunoglobulin administered simultaneously with the first vaccine dose. In both vaccinated groups, the rate of seroconversion was found to be higher than 90% at month 1, reaching 100% and 97.8% at month 2 in groups 1 and 3, respectively, and 100% at month 7. In the group receiving both vaccine and immunoglobulin, antibody production was somewhat slower and the final titres were, on average, slightly lower than those obtained in the group with the vaccine alone (GMT 2488 and 3614 mIU ml-1 respectively; p = 0.02). The vaccine appeared to be highly immunogenic in all subjects and was also well tolerated. The slight inhibition of antibody production, induced by the concurrent administration of immunoglobulin, does not affect the overall protection afforded by the vaccine. We conclude that simultaneous active and passive hepatitis A immunizations can be recommended.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8212822     DOI: 10.1016/0264-410x(93)90128-k

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  Preventing hepatitis A infections. National Advisory Committee on Immunization statement. Laboratory Centre for Disease Control.

Authors: 
Journal:  Can Fam Physician       Date:  1995-07       Impact factor: 3.275

Review 2.  Clinical development of a new inactivated hepatitis A vaccine.

Authors:  E Vidor; B Fritzell; S Plotkin
Journal:  Infection       Date:  1996 Nov-Dec       Impact factor: 3.553

Review 3.  Factors That Influence the Immune Response to Vaccination.

Authors:  Petra Zimmermann; Nigel Curtis
Journal:  Clin Microbiol Rev       Date:  2019-03-13       Impact factor: 26.132

Review 4.  Hepatitis A immunisation in persons not previously exposed to hepatitis A.

Authors:  Greg J Irving; John Holden; Rongrong Yang; Daniel Pope
Journal:  Cochrane Database Syst Rev       Date:  2019-12-17

Review 5.  New hepatitis A vaccines and their role in prevention.

Authors:  D B Strader; L B Seeff
Journal:  Drugs       Date:  1996-03       Impact factor: 9.546

Review 6.  Hepatitis A immunisation in persons not previously exposed to hepatitis A.

Authors:  Greg J Irving; John Holden; Rongrong Yang; Daniel Pope
Journal:  Cochrane Database Syst Rev       Date:  2012-07-11

Review 7.  Active immunization in the United States: developments over the past decade.

Authors:  P H Dennehy
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

Review 8.  Aventis Pasteur vaccines containing inactivated hepatitis A virus: a compilation of immunogenicity data.

Authors:  E Vidor; R Dumas; V Porteret; F Bailleux; K Veitch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-06       Impact factor: 3.267

Review 9.  Safety and effectiveness of the new inactivated hepatitis A virus vaccine.

Authors:  J Furesz; D W Scheifele; L Palkonyay
Journal:  CMAJ       Date:  1995-02-01       Impact factor: 8.262

10.  Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020.

Authors:  Noele P Nelson; Mark K Weng; Megan G Hofmeister; Kelly L Moore; Mona Doshani; Saleem Kamili; Alaya Koneru; Penina Haber; Liesl Hagan; José R Romero; Sarah Schillie; Aaron M Harris
Journal:  MMWR Recomm Rep       Date:  2020-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.